A phase II trial of low-dose metronomic oral vinorelbine as salvage treatment in advanced non-small cell lung cancer (NSCLC)

被引：0

作者：

Agelaki, S. ^{[1
]}

Kontopodis, E. D. ^{[1
]}

Kentepozidis, N. ^{[1
]}

Giassas, S. ^{[1
]}

Vamvakas, L. ^{[1
]}

Androulakis, N. ^{[1
]}

Kotsakis, K. ^{[1
]}

Sfakiotaki, G. ^{[1
]}

Mavroudis, D. ^{[1
]}

Georgoulias, V ^{[1
]}

机构：

[1] Univ Gen Hosp Heraklion, Dept Med Oncol, Iraklion, Greece

来源：

JOURNAL OF THORACIC ONCOLOGY | 2009年 / 4卷 / 09期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S448 / S448

页数：1

共 50 条

[31] Metronomic oral vinorelbine in a real-world population of advanced non-small cell lung cancer patients [J].

Estevinho, Fernanda ;

Gomes, Rita ;

Hasmucrai, Direndra ;

Barata, Fernando .

PULMONOLOGY, 2022, 28 (05) :368-375

[32] Gemcitabine plus vinorelbine (GEMVIN) in the treatment of advanced non-small cell lung cancer (NSCLC). Sequential phase I and phase II trials [J].

Cigolari, S ;

Gridelli, C ;

Frontini, L ;

Gulisano, M ;

Robbiati, SF ;

Farris, A ;

Clerici, M ;

Castiglione, F ;

Piazza, E ;

Ianniello, GP ;

Perrone, F .

ANNALS OF ONCOLOGY, 1998, 9 :87-87

[33] A phase II study of vinorelbine in patients with advanced non-small cell lung cancer [J].

Evans, TRJ ;

Mansi, JL ;

Morgan, DAL ;

Gyi, KM ;

Banham, SW ;

Milroy, R .

ONCOLOGY REPORTS, 1997, 4 (06) :1337-1341

[34] Vinorelbine-gemcitabine in advanced non-small-cell lung cancer (NSCLC):: An AASLC phase II trial [J].

Krajnik, G ;

Mohn-Staudner, A ;

Thaler, J ;

Greil, R ;

Schmeikal, S ;

Marhold, F ;

Deutsch, J ;

Preiss, P ;

Malayeri, R ;

Schäfer-Prokop, C ;

Wein, W ;

Huber, H ;

Pirker, R .

ANNALS OF ONCOLOGY, 2000, 11 (08) :993-998

[35] Phase I/II trial of low dose cyclosporin A with EP for advanced non-small cell lung cancer [J].

Ross, HJ ;

Cho, J ;

Osann, K ;

Wong, SF ;

Ramsinghani, N ;

Williams, J ;

DowneyHurtado, N ;

Slater, LM .

LUNG CANCER, 1997, 18 (02) :189-198

[36] Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer [J].

Zwitter, M ;

Kovac, V ;

Smrdel, U ;

Kocijancic, I ;

Segedin, B ;

Vrankar, M .

ANTI-CANCER DRUGS, 2005, 16 (10) :1129-1134

[37] A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group [J].

Kontopodis, Emmanouil ;

Hatzidaki, Dora ;

Varthalitis, Ioannis ;

Kentepozidis, Nikolaos ;

Giassas, Stylianos ;

Pantazopoulos, Nikolaos ;

Vardakis, Nikolaos ;

Rovithi, Maria ;

Georgoulias, Vassilis ;

Agelaki, Sofia .

JOURNAL OF CHEMOTHERAPY, 2013, 25 (01) :49-55

[38] Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: a phase II trial of efficacy and toxicity [J].

Kanard, A ;

Jatoi, A ;

Castillo, R ;

Geyer, S ;

Schulz, TK ;

Fitch, TR ;

Rowland, KM ;

Nair, S ;

Krook, JE ;

Kugler, JW .

LUNG CANCER, 2004, 43 (03) :345-353

[39] Docetaxel (Taxotere) and vinorelbine in the treatment of advanced non-small cell lung cancer: Preliminary results of a phase I/II trial [J].

Miller, VA .

SEMINARS IN ONCOLOGY, 1997, 24 (04) :S15-S17

[40] Gemcitabine, vinorelbine and cisplatin combination chemotherapy in advanced non-small cell lung cancer:: a phase II trial [J].

Laack, E ;

Mende, T ;

Dürk, H ;

Kneba, M ;

Dickgreber, N ;

Welte, T ;

Müller, T ;

Scholtze, J ;

Graeven, U ;

Jasiewicz, Y ;

Edler, L ;

Hossfeld, DK .

EUROPEAN JOURNAL OF CANCER, 2002, 38 (05) :654-660

← 1 2 3 4 5 →